APA (7th ed.) Citation

J, A., E, D., E, H., R, S., S, G., S, E. M., . . . C, R. (2021). COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. The Lancet. Rheumatology, 3(6), e419. https://doi.org/10.1016/S2665-9913(21)00059-X

Chicago Style (17th ed.) Citation

J, Avouac, et al. "COVID-19 Outcomes in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Treated with Rituximab: A Cohort Study." The Lancet. Rheumatology 3, no. 6 (2021): e419. https://doi.org/10.1016/S2665-9913(21)00059-X.

MLA (9th ed.) Citation

J, Avouac, et al. "COVID-19 Outcomes in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Treated with Rituximab: A Cohort Study." The Lancet. Rheumatology, vol. 3, no. 6, 2021, p. e419, https://doi.org/10.1016/S2665-9913(21)00059-X.